Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE | Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...